Abstract
Purpose
Germline promoter hypermethylation of BRCA1 and BRCA2 genes is an alternative event of gene silencing that has not been widely investigated in hereditary breast and ovarian cancer (HBOC) syndrome.
Methods
We analyzed germline BRCA promoter hypermethylation in HBOC patients with and without BRCA mutations and control subjects, using a recently developed BRCA methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
Results
Neither the patients tested nor the control subjects showed germline hypermethylation of the BRCA1 and BRCA2 promoter regions analyzed.
Conclusions
Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA.
Similar content being viewed by others
References
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16(3):481–8.
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564–9.
Hedenfalk IA. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst. 2002;94(13):960–1.
Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumours identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 2005;11(3):1146–53.
Hitchins M, Williams R, Cheong K, Halani N, Lin VA, Packham D, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 2005;129(5):1392–9.
Hitchins MP, Wong JJ, Shuters G, Suter CM, Martin DI, Hawkins NJ, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2005;356(7):697–705.
Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001–7.
Bosviel R, Garcia S, Lavediaux G, Michard E, Dravers M, Kwiatkowski F, et al. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol. 2012;36:e177–82.
Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cell is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat. 2011;129(1):69–77.
Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, et al. Levels of DNA methylation vary at CpG sites across the BRCA1 promoter, and differ according to triple negative and “BRCA-like” status, in both blood and tumour DNA. PLoS One. 2016;11(7):e0160174.
Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A, kConFab Investigators. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008;10(1):R12.
Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila). 2001;4(1):23–33.
Nygren AOH, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33(14):e128.
Pérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 2010;12(4):498–504.
Vos S, Moelans CB, van Diest PJ. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res. 2017;19(1):64.
Graña B, Lastra E, Llort G, Brunet J, Isla D. SEOM clinical guidelines for hereditary cancer. Clin Transl Oncol. 2011;13(8):580–6.
Lips EH, Mulder L, Oonk A, van der Kolk LE, Hoervorst FB, Imholz AL, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. BJC. 2013;108(10):2172–7.
Wojdacz T, Thestrup BB, Overgaard J, Hansen LL. Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol. 2011;6:116.
Chen Y, Toland AE, McLennan J, Fridlyand J, Crawford B, Costello JF, et al. Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet Test. 2006;10(4):281–4.
Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Epidemiology. 2014;148(3):615–22.
Pang D, Zhao Y, Xue W, Shan M, Chen Y, Zhang Y, et al. Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese. Med Oncol. 2012;29(3):1561–8.
Zhang L, Long X. Association of BRCA1 promoter methylation with sporadic breast cancers: evidence from 40 studies. Sci Rep. 2015;5:17869.
Acknowledgements
The genomic analyses were performed at the Centre for Omic Sciences (COS) of the Universitat Rovira i Virgili.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
MS-MLPA reagents were made available by MRC-Holland, Amsterdam, the Netherlands. The ME053-X1 BRCA1-BRCA2 probemix was designed by Lilit Atanesyan. MRC-Holland was not involved in the design or analysis of the experiments or in the writing of the manuscript.
Ethical approval
This study was approved by the Ethics Committee of Clinical Research of Sant Joan University Hospital, and written informed consent was obtained from all participants.
Rights and permissions
About this article
Cite this article
Rodríguez-Balada, M., Roig, B., Melé, M. et al. Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients. Clin Transl Oncol 20, 1226–1231 (2018). https://doi.org/10.1007/s12094-018-1837-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-018-1837-0